Zhou C, Ramalingam SS, Kim TM, et al. - In patients with previously treated EGFR exon 20 insertion (EGFRex20ins)-positive metastatic non–small cell lung cancer (mNSCLC), a favorable risk-benefit profile of mobocertinib (an oral tyrosine kinase inhibitor) was evident in this study.

• In this nonrandomized clinical trial including the platinum-pretreated patients (PPP) (n = 114) and EXCLAIM (an extension cohort) (n = 96) cohorts, mobocertinib demonstrated antitumor activity in patients with platinum-pretreated EGFRex20ins-positive mNSCLC.

• Treatment with mobocertinib was associated with a confirmed objective response rate of 28%, median duration of response of 17.5 months, and median progression-free survival of 7.3 months by independent review committee assessments.

• Regarding safety, gastrointestinal and cutaneous adverse events occurred, which were manageable to a large extent.

• Overall, mobocertinib conferred a clinically meaningful benefit and displayed a manageable safety profile in this patient population.